# Study of Lisaftoclax (APG-2575) Single Agent and Combination With Therapy in Patients Relapsed/Refractory AML

Source: https://onco.cc/trials/nct04501120/  
OnCo record `nct04501120` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of Azacitidine, Olverembatinib in acute myeloid leukaemia, run by Ascentage Pharma Group Inc., now recruiting.

## Summary

Study of Lisaftoclax (APG-2575) Single Agent and Combination With Therapy in Patients Relapsed/Refractory AML is a phase 1/2 interventional study registered as NCT04501120 by Ascentage Pharma Group Inc., with 682 participants planned, started 2020-09-28 and due to reach its primary completion in 2028-09. Interventions recorded: Lisaftoclax (APG-2575), Reduced-dose HHT, standard-dose HHT, Azacitidine, Lisaftoclax (APG-2575). Conditions listed: Relapsed/Refractory Acute Myeloid Leukaemia, Myeloid Malignancy. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT04501120
- Phase: 1/2
- Setting: A Phase Ib Study of the Safety, Pharmacokinetic of Lisaftoclax (APG-2575) Single Agent and in Combination With Homoharringtonine or Azacitidine in Patients With Relapsed/Refractory AML
- Sponsor: Ascentage Pharma Group Inc.
- Enrolled: 682

## Sources

- ClinicalTrials.gov NCT04501120: https://clinicaltrials.gov/study/NCT04501120

## Connected records

- cancers: [Acute myeloid leukaemia](https://onco.cc/cancers/aml/)
- drugs: [Azacitidine](https://onco.cc/drugs/azacitidine/), [Olverembatinib](https://onco.cc/drugs/olverembatinib/)
- companies: [Ascentage Pharma](https://onco.cc/companies/ascentage-pharma/)

---
JSON: https://onco.cc/api/v1/entities/nct04501120.json